期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

细菌耐药突变选择窗与抗感染药物防突变浓度的研究与应用

下载PDF
导出
作者 李绍红 李泽民
机构地区 天津中医药大学第二附属医院检验科
出处 《检验医学与临床》 CAS 2010年第10期992-997,共6页 Laboratory Medicine and Clinic
关键词 抗药性 细菌 突变选择窗 防突变浓度
分类号 R969.4 [医药卫生—药理学]
  • 相关文献

参考文献27

  • 1Drlica K.Antibiotic resistance:can we beat the bugs[J].Drug Discov Today,2001,6:714-716.
  • 2Drlica K.The mutant selection concentration and antimicrobial resistance[J].J Antimicrob Chemother,2003,52(1):11-17.
  • 3Drlica K.A strategy for fighting antibiotic resistance[J].ASM News,2001,67:27-33.
  • 4Zhao XL,Drlica K.Restricting the selection of antibiotic resistant mutant s:a general strategy derived f rom fluoroquinolone studies[J].Clin Infect Dis,2006,33 (3):147-156.
  • 5Dong Y,Zhao X,Kreiswirth BN,et al.Mutant preventionconcentration as a measure of antibiotic potency:studies withclinical isolates of mycobacterium uberculosis[J].Antimicrob Agents Chemother,2006,44:2581-2584.
  • 6Zhao X,Drlica K.Restricting the selection of antibiotic resistant mutant bacteria:measurement and potential use of the mutant selection window[J].J Infect Dis,2002,185:561-565.
  • 7Zhao J,Dong Y,Zhao X,et al.Selection of antibiotic resistant bacterial mutants:allelic diversity among fluoroquilonone resistant mutantions[J].J Infect Dis,2002,182:517-525.
  • 8Nakamura S.Mechanisms of quinolone resistance[J].J Infect Chemother,2007,3:128-138.
  • 9Blondeau J M,Zhao X,Hansen J,et al.Mutant prevention concentration of fluoroquinolones for clinical isolates of streptococcus pneumoniae[J].Antimicrob Agents Chemother,2006,45:433-438.
  • 10Hansen G,Metzler K,Drlica K,et al.Mutant prevention concentration for gemifloxacin with clinical isolates of streptococcus pneumoniae[J].Antimicro Agents Chemother,2003,47:440 -441.

二级参考文献12

  • 1谢林,刘晓东,王大为.注射用阿奇霉素的生物利用度研究[J].江苏药学与临床研究,2004,12(3):12-14. 被引量：1
  • 2Drlica K.The mutant selection concentration and antimicrobial resistance[J].J Antimicrob Chemotherk,2003;52:11-17.
  • 3Zhao X,Drlica K.Restricting the selection of antibiotic-resistant mutant bacteria:measurement and potential use of the mutant selection window[J].J Infect Dis,2002;185:561-565.
  • 4Blondeau JM,Zhao X,Hansen J,et al.Mutant prevention concentration of fluoroquinolones for clinical isolates of Streptococcus pneumoniae[J].Antimicrob Agents Chemother,2001;45:433-438.
  • 5Burke J,WarginW,Sherertz R,et al.Pharmacoki-netics of intravenous chloramphenicol sodium succinate in adult patients with normal renal and hepatic function[J].J Pharmacokinet Biopharm,1982;10:601-614.
  • 6Bates R,Nahata M,Jones J,et al.Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis[J].Chest,1997;112:1208-1213.
  • 7Smith HJ,Nichol KA,Hoban DJ,et al.Stretching the mutant prevention concentration (MPC) beyond its limits[J].Antimicrob Chemother,2003;51:1323-1325.
  • 8Zhao X.Clarification of MPC and the mutant selection window concept[J].Antimicrob Chemother,2003;52:731.
  • 9Lu T,Zhao X,Li X,et al.Effect of chloramphenicol,erythromycin,moxifloxacin,penicillin and tetracycline concentration on the recovery of resistant mutants of Mycobacterium smegmatis and Staphylococcus aureus[J].Antimicrob Chemother,2003;52:61-64.
  • 10王建,侯艳宁,刘会臣,胡玉钦,李新芳,王虎军.国产利福平胶囊的人体相对生物利用度[J].中国药房,1998,9(5):224-225. 被引量：5

共引文献11

检验医学与临床
2010年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部